

# **Dyslipidemia in Primary Care:**

**Addressing Barriers to Optimal Lipid Management** 

#### YOU ARE INVITED TO JOIN US...

for an interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice.

J	oin	us	for	a gr	oup l	learnii	ng	sess	ion

Dutc.					
Location:					
Program Sta	art Time:	Program End Time:			
Speaker(s):	N	Moderator:			
Registration / N	Meal Comments:				
RSVP:					

### **AGENDA**

Data:

## **Dyslipidemia in Primary Care:**

**Addressing Barriers to Optimal Lipid Management** 

- The following topics will be covered during this program:
  - ✓ Centrality of LDL Cholesterol
  - Guidelines vs. Real World
  - Limitations of Current Therapies
  - Non-Statin Strategies to Reduce LDL-C
  - ✓ PCSK9 Inhibitors: News and Pearls.
  - √ Improving Outcomes in Our Patients

### **LEARNING OBJECTIVES**

#### Upon completion of this activity, participants will be able to:

- Recognize the centrality of LDL-C and its cumulative exposure to increased risk of ASCVD events
- Evaluate the limitations of current lipid lowering agents and assess recommendations for lipid lowering agents beyond, or in addition to, statin therapy for high risk patients
  - Identify those patients who would benefit from additional therapy beyond statins to reduce CV risk
    - Explain the latest clinical data for PCSK9 inhibitors and use effective strategies to integrate the data into clinical care to reduce the risk for CV events
      - Appropriately apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics

